Display options
Cite
Yakhine-Diop SMS, Morales-García JA, Niso-Santano M, et al. Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease. Aging (Albany NY). 2020;12(17):16690-16708doi: 10.18632/aging.103992.
Yakhine-Diop, S. M. S., Morales-García, J. A., Niso-Santano, M., González-Polo, R. A., Uribe-Carretero, E., Martinez-Chacon, G., Durand, S., Maiuri, M. C., Aiastui, A., Zulaica, M., Ruíz-Martínez, J., López de Munain, A., Pérez-Tur, J., Pérez-Castillo, A., Kroemer, G., Bravo-San Pedro, J. M., & Fuentes, J. M. (2020). Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease. Aging, 12(17), 16690-16708. https://doi.org/10.18632/aging.103992
Yakhine-Diop, Sokhna M S, et al. "Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease." Aging vol. 12,17 (2020): 16690-16708. doi: https://doi.org/10.18632/aging.103992
Yakhine-Diop SMS, Morales-García JA, Niso-Santano M, González-Polo RA, Uribe-Carretero E, Martinez-Chacon G, Durand S, Maiuri MC, Aiastui A, Zulaica M, Ruíz-Martínez J, López de Munain A, Pérez-Tur J, Pérez-Castillo A, Kroemer G, Bravo-San Pedro JM, Fuentes JM. Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease. Aging (Albany NY). 2020 Sep 09;12(17):16690-16708. doi: 10.18632/aging.103992. Epub 2020 Sep 09. PMID: 32903216; PMCID: PMC7521510.
Copy Download .nbib Format: NLM
Share it on

Aging (Albany NY). 2020 Sep 09;12(17):16690-16708. doi: 10.18632/aging.103992. Epub 2020 Sep 09.

Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease.

Aging

Sokhna M S Yakhine-Diop, José A Morales-García, Mireia Niso-Santano, Rosa A González-Polo, Elisabet Uribe-Carretero, Guadalupe Martinez-Chacon, Sylvere Durand, Maria Chiara Maiuri, Ana Aiastui, Miren Zulaica, Javier Ruíz-Martínez, Adolfo López de Munain, Jordi Pérez-Tur, Ana Pérez-Castillo, Guido Kroemer, José M Bravo-San Pedro, José M Fuentes

Affiliations

  1. Departamento de Bioquímica y Biología Molecular y Genética. Facultad de Enfermería y Terapia Ocupacional. Universidad de Extremadura, Cáceres, Spain.
  2. Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  3. Instituto Universitario de Investigación Biosanitaria de Extremadura (INUBE), Cáceres, Spain.
  4. Instituto de Investigaciones Biomédicas (CSIC-UAM) "Alberto Sols" (CSIC-UAM), Madrid, Spain.
  5. Departamento de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
  6. Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.
  7. Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Inserm U1138, Université de Paris, Sorbonne Université, Paris, France.
  8. Cell Culture Platform, Biodonostia Health Research Institute, San Sebastián, Spain.
  9. Neuroscience Area of Biodonostia Health Research Institute, Donostia University Hospital, San Sebastián, Spain.
  10. , Donostia University Hospital, Department of Neurology, OSAKIDETZA, Spain.
  11. Ilundain Foundation, San Sebastian, Spain.
  12. Department of Neurosciences, University of the Basque Country UPV-EHU, San Sebastián, Spain.
  13. Instituto de Biomedicina de Valencia-CSIC, Unidad de Genética Molecular, Valencia, Spain.
  14. Unidad Mixta de Genética y Neurología, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
  15. , Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, France.
  16. Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.
  17. Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
  18. Departamento de Fisiología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.

PMID: 32903216 PMCID: PMC7521510 DOI: 10.18632/aging.103992

Abstract

The research of new biomarkers for Parkinson's disease is essential for accurate and precocious diagnosis, as well as for the discovery of new potential disease mechanisms and drug targets. The main objective of this work was to identify metabolic changes that might serve as biomarkers for the diagnosis of this neurodegenerative disorder. For this, we profiled the plasma metabolome from mice with neurotoxin-induced Parkinson's disease as well as from patients with familial or sporadic Parkinson's disease. By using mass spectrometry technology, we analyzed the complete metabolome from healthy volunteers compared to patients with idiopathic or familial (carrying the G2019S or R1441G mutations in the

Keywords: Parkinson’s disease; bile acids; biomarkers; metabolism; purines

References

  1. Mov Disord. 2007 Feb 15;22(3):377-81 - PubMed
  2. Am J Epidemiol. 1996 Sep 1;144(5):480-4 - PubMed
  3. N Engl J Med. 1998 Oct 8;339(15):1044-53 - PubMed
  4. J Hepatol. 2004 Mar;40(3):539-51 - PubMed
  5. Neurogenetics. 2005 Dec;6(4):171-7 - PubMed
  6. Am J Epidemiol. 2007 Sep 1;166(5):561-7 - PubMed
  7. Mol Neurodegener. 2019 Jan 11;14(1):3 - PubMed
  8. Parkinsonism Relat Disord. 2018 Aug;53:82-88 - PubMed
  9. Proc Soc Exp Biol Med. 1991 Mar;196(3):235-52 - PubMed
  10. Parkinsonism Relat Disord. 2014 May;20(5):535-40 - PubMed
  11. Neurology. 2015 Sep 8;85(10):838-9 - PubMed
  12. JAMA. 2014 Apr 23-30;311(16):1670-83 - PubMed
  13. Mol Neurobiol. 2019 May;56(5):3437-3450 - PubMed
  14. BMC Neurol. 2019 Jan 5;19(1):4 - PubMed
  15. Scand J Clin Lab Invest. 1992 Sep;52(5):425-30 - PubMed
  16. Lancet. 2007 Dec 1;370(9602):1829-39 - PubMed
  17. J Parkinsons Dis. 2013 Jan 1;3(3):363-70 - PubMed
  18. Metabolomics. 2018;14(1):1 - PubMed
  19. Nat Rev Genet. 2006 Apr;7(4):306-18 - PubMed
  20. Nat Rev Mol Cell Biol. 2016 Jul;17(7):451-9 - PubMed
  21. Arch Neurol. 2009 Dec;66(12):1460-8 - PubMed
  22. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 1;1081-1082:101-108 - PubMed
  23. Exp Neurobiol. 2019 Oct 31;28(5):554-567 - PubMed
  24. J Proteome Res. 2015 Jan 2;14(1):467-78 - PubMed
  25. Toxicology. 2014 Oct 3;324:1-9 - PubMed
  26. Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1006-11 - PubMed
  27. Int J Cardiol. 2016 Jun 15;213:8-14 - PubMed
  28. Mol Neurobiol. 2018 Aug;55(8):6319-6328 - PubMed
  29. Med Hypotheses. 2020 Jan;134:109436 - PubMed
  30. Neurology. 2017 Feb 28;88(9):862-869 - PubMed
  31. Neuron. 2004 Nov 18;44(4):595-600 - PubMed
  32. N Engl J Med. 1993 Feb 4;328(5):313-8 - PubMed
  33. Cell. 2016 Nov 3;167(4):915-932 - PubMed
  34. Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19(4):220-5 - PubMed
  35. J Biomed Sci. 2009 Jul 13;16:63 - PubMed
  36. Mov Disord. 2017 Sep;32(9):1264-1310 - PubMed
  37. Mov Disord. 2013 Oct;28(12):1620-1 - PubMed
  38. Arthritis Rheum. 2008 Nov 15;59(11):1549-54 - PubMed
  39. Nat Med. 2016 Oct 06;22(10):1079-1089 - PubMed
  40. Mov Disord. 2013 Oct;28(12):1653-60 - PubMed
  41. Neurology. 2018 Jan 30;90(5):e404-e411 - PubMed
  42. Mol Neurobiol. 2019 Apr;56(4):2466-2481 - PubMed
  43. Mov Disord. 2008 May 15;23(7):1013-1018 - PubMed
  44. Clin Neurol Neurosurg. 2009 Nov;111(9):724-8 - PubMed
  45. Neurology. 2008 May 20;70(21):1972-9 - PubMed
  46. J Neurol Neurosurg Psychiatry. 2016 Mar;87(3):295-301 - PubMed
  47. Neurodegener Dis. 2011;8(4):252-8 - PubMed
  48. Cell Mol Life Sci. 2013 Jan;70(1):121-36 - PubMed
  49. Brain. 2008 Feb;131(Pt 2):389-96 - PubMed
  50. Neurobiol Aging. 2015 Feb;36(2):1160-73 - PubMed
  51. Parkinsonism Relat Disord. 2015 Nov;21(11):1371-2 - PubMed
  52. Mov Disord. 2011 Jan;26(1):176-81 - PubMed
  53. Lancet Neurol. 2008 Jul;7(7):583-90 - PubMed
  54. Mov Disord. 2017 Oct;32(10):1409-1422 - PubMed
  55. Biomark Med. 2010 Oct;4(5):701-12 - PubMed
  56. Am J Epidemiol. 2006 Nov 15;164(10):998-1002 - PubMed
  57. Int J Neurosci. 2015;125(11):838-44 - PubMed
  58. PLoS One. 2009 Oct 22;4(10):e7551 - PubMed
  59. Mov Disord. 2019 Mar;34(3):386-395 - PubMed
  60. Ann Neurol. 2019 Aug;86(2):251-263 - PubMed
  61. Metabolites. 2018 Oct 31;8(4): - PubMed

Publication Types